Ciro Costagliola1, Francesco Semeraro2, Roberto dell'Omo1, Mario R Romano3, Andrea Russo2, Fabiana Aceto4, Rodolfo Mastropasqua5, Antonio Porcellini6. 1. Eye Clinic, Department of Health Sciences, University of Molise, Campobasso, Italy. 2. Eye Clinic, Department of Neurological and Vision Sciences, University of Brescia, Brescia, Italy. 3. Department of Neuroscience, Reproductive and Odontostomatological Sciences, "Federico II" University of Naples, Naples, Italy. 4. Department of Medicine & Health Sciences, University of Molise, Campobasso, Italy. 5. Department of Ophthalmology, University of Verona, Verona, Italy. 6. Department of Structural and Functional Biology, "Federico II" University of Naples, Naples, Italy.
Abstract
AIMS: To investigate aqueous humour changes in vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) levels in patients with choroidal neovascularisation (CNV) secondary to pathological myopia (mCNV) before and after intravitreal ranibizumab injection (IVR). METHODS: This was a prospective, case-control study investigating aqueous levels of VEGF and PEDF in eyes with mCNV treated with IVR. RESULTS: Mean VEGF and PEDF levels in the aqueous humour of control patients were 25.7±4.9 pg/mL and 12.6±3.5 ng/mL, respectively. Lower levels of both VEGF (19.5±5.4 pg/mL) and PEDF (4.7±2.2 ng/mL) were found in patients with mCNV before IVR. After IVR, aqueous VEGF levels significantly reduced to 6.5±2.7 pg/mL, while PEDF levels significantly increased to 35.8±11.4 ng/mL. VEGF and PEDF levels significantly correlated with each other, and with best-corrected visual acuity and central retinal thickness. CONCLUSIONS: The VEGF and PEDF levels in aqueous humour were significantly lower in the myopic group than in controls. Moreover, IVR resulted in reduced VEGF and increased PEDF levels in patients with mCNV. In mCNV, neovascularisation is associated with inappropriate VEGF and PEDF expression. A balance between VEGF and PEDF is crucial to prevent CNV development. TRIAL REGISTRATION NUMBER: NCT02175940. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIMS: To investigate aqueous humour changes in vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) levels in patients with choroidal neovascularisation (CNV) secondary to pathological myopia (mCNV) before and after intravitreal ranibizumab injection (IVR). METHODS: This was a prospective, case-control study investigating aqueous levels of VEGF and PEDF in eyes with mCNV treated with IVR. RESULTS: Mean VEGF and PEDF levels in the aqueous humour of control patients were 25.7±4.9 pg/mL and 12.6±3.5 ng/mL, respectively. Lower levels of both VEGF (19.5±5.4 pg/mL) and PEDF (4.7±2.2 ng/mL) were found in patients with mCNV before IVR. After IVR, aqueous VEGF levels significantly reduced to 6.5±2.7 pg/mL, while PEDF levels significantly increased to 35.8±11.4 ng/mL. VEGF and PEDF levels significantly correlated with each other, and with best-corrected visual acuity and central retinal thickness. CONCLUSIONS: The VEGF and PEDF levels in aqueous humour were significantly lower in the myopic group than in controls. Moreover, IVR resulted in reduced VEGF and increased PEDF levels in patients with mCNV. In mCNV, neovascularisation is associated with inappropriate VEGF and PEDF expression. A balance between VEGF and PEDF is crucial to prevent CNV development. TRIAL REGISTRATION NUMBER: NCT02175940. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Rodolfo Mastropasqua; Emma Di Carlo; Carlo Sorrentino; Cesare Mariotti; Lyndon da Cruz Journal: J Clin Med Date: 2019-10-19 Impact factor: 4.241
Authors: Davide Allegrini; Diego Vezzola; Alfredo Borgia; Raffaele Raimondi; Tania Sorrentino; Domenico Tripepi; Elisa Stradiotto; Marco Alì; Giovanni Montesano; Mario R Romano Journal: J Clin Med Date: 2022-08-26 Impact factor: 4.964